副腎性器症候群治療の世界市場レポート 2025年

副腎性器症候群治療市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.0%で、161億9,000万米ドルに成長します。予測期間中の成長は、遺伝子研究の進歩、患者人口の増加、標的治療の採用拡大、新興市場におけるヘルスケアインフラの拡大、希少疾患治療に対する政府助成金の拡大などが要因と考えられます。この期間の主な動向としては、個別化医療の台頭、遺伝子治療アプリケーションの採用、デジタルヘルスツールの統合、非侵襲的診断技術の開発、製薬企業と研究機関の提携などが挙げられます。

個別化医療の採用拡大が副腎性器症候群治療市場の拡大を牽引すると予想されます。個別化医療は、個人の遺伝子プロファイル、ライフスタイル、特定の健康ニーズに合わせて治療をカスタマイズし、有効性と安全性を高めるものです。個別化医療への嗜好の高まりは、遺伝学の進歩、オーダーメイド治療に対する患者の需要の高まり、ヘルスケア技術の向上によってもたらされています。副腎性器症候群の文脈では、個別化治療は患者固有の遺伝的体質とホルモンレベルに基づいて設計され、副作用を最小限に抑えながら治療結果を最適化します。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、FDAによる個別化治療の承認件数は、2022年の6件から2023年には16件に増加し、うち7件はがん、3件はその他の疾患であったと報告しました。その結果、個別化医療の採用が増加し、副腎性器症候群治療市場の成長に寄与すると予想されます。

副腎性器症候群治療市場の主要企業は、アンメット・メディカル・ニーズに対応し、患者の予後を改善し、希少疾患や複雑な疾患に的を絞ったソリューションを提供することで市場でのプレゼンスを拡大するため、革新的な希少疾病用医薬品などの先進的な治療法の開発に注力しています。希少疾病用医薬品は、既存の治療選択肢が限られているか、あるいは全くない、希少でしばしば重篤な疾病のために開発された特殊な医薬品です。例えば、2024年12月、米国のバイオテクノロジー企業であるニューロクライン・バイオサイエンシズは、副腎性器症候群の一種である古典的な先天性副腎過形成（CAH）の小児および成人に対する新規治療薬であるクレネシティ（クリネカーフォント）の承認を米国食品医薬品局（FDA）から取得したと発表しました。この承認は、CAHに対する70年ぶりの新たな治療選択肢を導入し、この稀な内分泌疾患の治療における重要なギャップを解決する画期的なものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界副腎性器症候群治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の副腎性器症候群治療市場：成長率分析
• 世界の副腎性器症候群治療市場の実績：規模と成長, 2019-2024
• 世界の副腎性器症候群治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界副腎性器症候群治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の副腎性器症候群治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ミネラルコルチコイド
• グルココルチコイド
• 世界の副腎性器症候群治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• 静脈内
• 吸入
• 世界の副腎性器症候群治療市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝子検査技術
• ホルモン補充療法
• 外科技術
• 世界の副腎性器症候群治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• その他の流通チャネル
• 世界の副腎性器症候群治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア設定
• 世界の副腎性器症候群治療市場ミネラルコルチコイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• フルドロコルチゾン
• その他のミネラルコルチコイド
• 世界の副腎性器症候群治療市場グルココルチコイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒドロコルチゾン
• プレドニゾロン
• デキサメタゾン
• その他のグルココルチコイド

第7章 地域別・国別分析

• 世界の副腎性器症候群治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の副腎性器症候群治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 副腎性器症候群治療市場：競合情勢
• 副腎性器症候群治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Lundbeck A/S Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Neurocrine Biosciences Inc.
• Sandoz Group AG
• IP Group Plc
• BridgeBio Pharma
• Bristol Laboratories Ltd
• Changi General Hospital Pte Ltd
• OMass Therapeutics
• Spruce Biosciences Inc.
• Axplora
• Diurnal Ltd.
• Alder Biopharmaceuticals Inc
• Adrenas Therapeutics Inc
• Crinetics Pharmaceuticals Inc.
• EffRx Pharmaceuticals
• Millendo Therapeutics Inc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 副腎性器症候群治療市場2029：新たな機会を提供する国
• 副腎性器症候群治療市場2029：新たな機会を提供するセグメント
• 副腎性器症候群治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Adrenogenital syndrome is a genetic disorder that affects the adrenal glands, causing an imbalance in hormone production, particularly cortisol and aldosterone. Treatment aims to restore hormonal balance through corticosteroids to manage symptoms and prevent complications such as adrenal crises and abnormal growth patterns.

The primary drug types for treating adrenogenital syndrome include mineralocorticoids and glucocorticoids. Mineralocorticoids are a class of steroid hormones that regulate mineral balance, particularly sodium and potassium, with aldosterone being the most well-known example. These drugs are administered via various routes, including oral, parenteral, intravenous, and inhalation methods, and utilize key technologies such as genetic testing, hormone replacement therapies, and surgical procedures. They are distributed through hospital and retail pharmacies, among others, and are used in hospitals, clinics, and home care settings.

The adrenogenital syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides adrenogenital syndrome treatment market statistics, including the adrenogenital syndrome treatment industry global market size, regional shares, competitors with the adrenogenital syndrome treatment market share, detailed adrenogenital syndrome treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the adrenogenital syndrome treatment industry. This adrenogenital syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adrenogenital syndrome treatment market size has grown strongly in recent years. It will grow from $12.08 billion in 2024 to $12.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth during the historical period can be attributed to greater awareness of rare diseases, a rising pediatric population, increased clinical awareness and education, a higher incidence of hormonal disorders, and improved access to healthcare services.

The adrenogenital syndrome treatment market size is expected to see strong growth in the next few years. It will grow to $16.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be driven by advancements in genetic research, a growing patient population, increased adoption of targeted therapies, expanding healthcare infrastructure in emerging markets, and greater government funding for rare disease treatments. Key trends in this period include the rise of personalized medicine, the adoption of gene therapy applications, the integration of digital health tools, the development of non-invasive diagnostic techniques, and collaborations between pharmaceutical companies and research institutions.

The increasing adoption of personalized medicine is expected to drive the expansion of the adrenogenital syndrome treatment market. Personalized medicine involves tailoring treatments to an individual's genetic profile, lifestyle, and specific health needs to enhance efficacy and safety. The growing preference for personalized medicine is driven by advancements in genetics, rising patient demand for customized treatments, and improvements in healthcare technologies. In the context of adrenogenital syndrome, personalized treatments are designed based on a patient's unique genetic makeup and hormone levels, optimizing therapeutic outcomes while minimizing side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that FDA approvals for personalized treatments increased to 16 in 2023, including seven for cancer and three for other conditions, up from six in 2022. As a result, the rising adoption of personalized medicine is expected to contribute to the growth of the adrenogenital syndrome treatment market.

Leading companies in the adrenogenital syndrome treatment market are focusing on developing advanced therapies, such as innovative orphan drugs, to address unmet medical needs, improve patient outcomes, and expand their market presence by offering targeted solutions for rare and complex disorders. Orphan drugs are specialized medications developed for rare and often severe diseases that have limited or no existing treatment options. For instance, in December 2024, Neurocrine Biosciences, a US-based biotech company, announced that it had received approval from the U.S. Food and Drug Administration (FDA) for CRENESSITY (crinecerfont), a novel treatment for children and adults with classic Congenital Adrenal Hyperplasia (CAH), a form of adrenogenital syndrome. This approval marks a significant breakthrough, introducing the first new therapeutic option for CAH in seventy years and addressing a critical gap in treating this rare endocrine disorder.

In November 2022, Neurocrine Biosciences, Inc., a US-based biotech company, acquired Diurnal Group plc for $58.03 million. This acquisition aims to strengthen Neurocrine Biosciences' portfolio in rare endocrine diseases and enhance its global market position in the treatment of hormonal disorders. Diurnal Group plc, a UK-based biotech company, specializes in developing therapies for chronic endocrine conditions, including adrenogenital syndrome.

Major players in the adrenogenital syndrome treatment market are Pfizer Inc., Thermo Fisher Scientific, Novartis AG, Teva Pharmaceutical Industries Ltd., Lundbeck A/S, Neurocrine Biosciences Inc., Sandoz Group AG, IP Group Plc, BridgeBio Pharma, Bristol Laboratories Ltd, Changi General Hospital Pte Ltd, OMass Therapeutics, Spruce Biosciences Inc., Axplora, Diurnal Ltd., Alder Biopharmaceuticals Inc, Adrenas Therapeutics Inc, Crinetics Pharmaceuticals Inc., EffRx Pharmaceuticals, and Millendo Therapeutics Inc.

North America was the largest region in the adrenogenital syndrome treatment market in 2024. The regions covered in adrenogenital syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adrenogenital syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adrenogenital syndrome treatment market consists of revenues earned by entities by providing services such as therapy services, psychological and psychosocial support services, telemedicine, and remote monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The adrenogenital syndrome treatment market also includes sales of androgen modulators, dietary and nutritional supplements, and diagnostic and monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adrenogenital Syndrome Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adrenogenital syndrome treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adrenogenital syndrome treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adrenogenital syndrome treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Mineralocorticoids; Glucocorticoids
• 2) By Route of Administration: Oral; Parenteral; Intravenous; Inhaled
• 3) By Technology: Genetic Testing Technologies; Hormone Replacement Therapies; Surgical Technologies
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Clinics; Home Care Settings
• Subsegments:
• 1) By Mineralocorticoids: Fludrocortisone; Other Mineralocorticoids
• 2) By Glucocorticoids: Hydrocortisone; Prednisolone; Dexamethasone; Other Glucocorticoids
• Companies Mentioned: Pfizer Inc.; Thermo Fisher Scientific; Novartis AG; Teva Pharmaceutical Industries Ltd.; Lundbeck A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adrenogenital Syndrome Treatment Market Characteristics

3. Adrenogenital Syndrome Treatment Market Trends And Strategies

4. Adrenogenital Syndrome Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Adrenogenital Syndrome Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adrenogenital Syndrome Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adrenogenital Syndrome Treatment Market Growth Rate Analysis
• 5.4. Global Adrenogenital Syndrome Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adrenogenital Syndrome Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adrenogenital Syndrome Treatment Total Addressable Market (TAM)

6. Adrenogenital Syndrome Treatment Market Segmentation

• 6.1. Global Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mineralocorticoids
• Glucocorticoids
• 6.2. Global Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Intravenous
• Inhaled
• 6.3. Global Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing Technologies
• Hormone Replacement Therapies
• Surgical Technologies
• 6.4. Global Adrenogenital Syndrome Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels
• 6.5. Global Adrenogenital Syndrome Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• 6.6. Global Adrenogenital Syndrome Treatment Market, Sub-Segmentation Of Mineralocorticoids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fludrocortisone
• Other Mineralocorticoids
• 6.7. Global Adrenogenital Syndrome Treatment Market, Sub-Segmentation Of Glucocorticoids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hydrocortisone
• Prednisolone
• Dexamethasone
• Other Glucocorticoids

7. Adrenogenital Syndrome Treatment Market Regional And Country Analysis

• 7.1. Global Adrenogenital Syndrome Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adrenogenital Syndrome Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adrenogenital Syndrome Treatment Market

• 8.1. Asia-Pacific Adrenogenital Syndrome Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adrenogenital Syndrome Treatment Market

• 9.1. China Adrenogenital Syndrome Treatment Market Overview
• 9.2. China Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adrenogenital Syndrome Treatment Market

• 10.1. India Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adrenogenital Syndrome Treatment Market

• 11.1. Japan Adrenogenital Syndrome Treatment Market Overview
• 11.2. Japan Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adrenogenital Syndrome Treatment Market

• 12.1. Australia Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adrenogenital Syndrome Treatment Market

• 13.1. Indonesia Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adrenogenital Syndrome Treatment Market

• 14.1. South Korea Adrenogenital Syndrome Treatment Market Overview
• 14.2. South Korea Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adrenogenital Syndrome Treatment Market

• 15.1. Western Europe Adrenogenital Syndrome Treatment Market Overview
• 15.2. Western Europe Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adrenogenital Syndrome Treatment Market

• 16.1. UK Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adrenogenital Syndrome Treatment Market

• 17.1. Germany Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adrenogenital Syndrome Treatment Market

• 18.1. France Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adrenogenital Syndrome Treatment Market

• 19.1. Italy Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adrenogenital Syndrome Treatment Market

• 20.1. Spain Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adrenogenital Syndrome Treatment Market

• 21.1. Eastern Europe Adrenogenital Syndrome Treatment Market Overview
• 21.2. Eastern Europe Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adrenogenital Syndrome Treatment Market

• 22.1. Russia Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adrenogenital Syndrome Treatment Market

• 23.1. North America Adrenogenital Syndrome Treatment Market Overview
• 23.2. North America Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adrenogenital Syndrome Treatment Market

• 24.1. USA Adrenogenital Syndrome Treatment Market Overview
• 24.2. USA Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adrenogenital Syndrome Treatment Market

• 25.1. Canada Adrenogenital Syndrome Treatment Market Overview
• 25.2. Canada Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adrenogenital Syndrome Treatment Market

• 26.1. South America Adrenogenital Syndrome Treatment Market Overview
• 26.2. South America Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adrenogenital Syndrome Treatment Market

• 27.1. Brazil Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adrenogenital Syndrome Treatment Market

• 28.1. Middle East Adrenogenital Syndrome Treatment Market Overview
• 28.2. Middle East Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adrenogenital Syndrome Treatment Market

• 29.1. Africa Adrenogenital Syndrome Treatment Market Overview
• 29.2. Africa Adrenogenital Syndrome Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adrenogenital Syndrome Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adrenogenital Syndrome Treatment Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adrenogenital Syndrome Treatment Market Competitive Landscape And Company Profiles

• 30.1. Adrenogenital Syndrome Treatment Market Competitive Landscape
• 30.2. Adrenogenital Syndrome Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Lundbeck A/S Overview, Products and Services, Strategy and Financial Analysis

31. Adrenogenital Syndrome Treatment Market Other Major And Innovative Companies

• 31.1. Neurocrine Biosciences Inc.
• 31.2. Sandoz Group AG
• 31.3. IP Group Plc
• 31.4. BridgeBio Pharma
• 31.5. Bristol Laboratories Ltd
• 31.6. Changi General Hospital Pte Ltd
• 31.7. OMass Therapeutics
• 31.8. Spruce Biosciences Inc.
• 31.9. Axplora
• 31.10. Diurnal Ltd.
• 31.11. Alder Biopharmaceuticals Inc
• 31.12. Adrenas Therapeutics Inc
• 31.13. Crinetics Pharmaceuticals Inc.
• 31.14. EffRx Pharmaceuticals
• 31.15. Millendo Therapeutics Inc

32. Global Adrenogenital Syndrome Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adrenogenital Syndrome Treatment Market

34. Recent Developments In The Adrenogenital Syndrome Treatment Market

35. Adrenogenital Syndrome Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Adrenogenital Syndrome Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adrenogenital Syndrome Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adrenogenital Syndrome Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer